7
Views
1
CrossRef citations to date
0
Altmetric
Original Paper

A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs

, , , , , , & show all
Pages 349-361 | Published online: 07 Jul 2009
 

Abstract

Background

Cord blood (CB) has been used as an alternative source of transplantable allogeneic stem cells for a variety of malignant and non-malignant diseases. However, we have demonstrated delayed recovery of T- and B-cell function, and T-cell subsets post unrelated CB transplantation (UCBT), and deficiencies of CB mononuclear cells (MNC) in producing cytokines, including G-CSF, GM-CSF, M-CSF, IL-12, and IL-15. In this study we have investigated the ex vivo generation of DC from CB versus mobilized adult peripheral blood (APB) for later use as adoptive cellular immonotherapy.

Methods

CB and APB-adherent MNC were cultured in serum-free media with GM-CSF, IL-4, FLT-3 ligand, tumor growth factor-β (TGF-β), and tumor necrosis factor-α (TNF-α) for 7 days. Morphology, phenotype, immunohistochemistry, clonogenic activity, and alloreactivity in MLR were evaluated.

Results

CB and APB monocyte-derived ex vivo expanded DC expressed similar DC markers CD83 (31.27±11.7% versus 34.0±5.2%, CB versus APB), CD1a (23.4±4.2% versus 27.6±6.3%), and CD80 (21.97±12.01% versus 27.7±5.95). Immunohistochemistry showed that cells with DC morphology expressed CD1a but not CD14. Neither FLT-3 ligand nor TGF-β enhanced DC expansion. Addition of 10% autologous plasma to CB cultures promoted greater cell survival and a 150% increase in CD1a+/CD80+ cell recovery. CB DC were 62% as effective stimulators of adult allogeneic T-cells as APB DC (p<0.05) in allogeneic MLR.

Discussion

While phenotypically similar, CB and APB DC have differential potency in allogeneic MLR, which may account for the difference in GvHD and infection incidence and severity between UCBT and allogeneic stem cell transplantation, and may require a different approach for adoptive cellular immunotherapy. The mechanism(s) associated with these differences require further elucidation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.